Not actual patients.
Symptoms illustrated.

Atopic Dermatitis?

ORYVE IT
RELIEVE IT

ZORYVE  has the power and
versatility to be your go-to topical.1
Not a steroid no boxed warning
ZORYVE (roflumilast) Cream 0.05% and ZORYVE (roflumilast) Cream 0.15%ZORYVE (roflumilast) Cream 0.05% and ZORYVE (roflumilast) Cream 0.15%
Simple once-daily treatmentSimple once-daily treatment

For age 2–5

For age 6+

“

I’ve learned that we can’t fix every problem on our own and it’s OK to get help.”

Simone Biles is speaking up about atopic dermatitis

Simone’s journey with mild to moderate atopic dermatitis showed her the value of getting help and having honest conversations with her dermatologist. Now, she’s partnering with ZORYVE to help others do the same.

Discover her experience

Simone Biles is a real patient treated with ZORYVE who was compensated for her time spent sharing her experience. Individual results may vary.

Powerful clearance
and itch relief in adult
and pediatric patients1

See efficacy data

Cream 0.15% for age 6+

Cream 0.05% for age 2–5

Established safety profile for
long-term use1,4,8

View safety data

Cream 0.15% for age 6+

Cream 0.05% for age 2–5

Simple, once-daily treatment1

Discover elegant formulations

31% of patients achieved vIGA-AD Success at Week 4 with ZORYVE cream 0.15% vs 14% with vehicle.1,5

32% of patients achieved WI-NRS Success at Week 4 with ZORYVE cream 0.15% vs 17% with vehicle.1,5

Results from a pooled analysis of INTEGUMENT-1 and INTEGUMENT-2 on the primary endpoint and WI-NRS Success at Week 4. Results should be interpreted in the context of individual study designs and analysis populations. Both individual studies showed significance vs vehicle at Week 4.

25% of patients achieved vIGA-AD Success at Week 4 with ZORYVE cream 0.05% vs 11% with vehicle.1,3

35% of patients achieved WI-NRS Success at Week 4 with ZORYVE cream 0.05% vs 18% with vehicle.3*

Result for WI-NRS Success at Week 4 for ZORYVE cream 0.05% is an exploratory analysis; therefore, no conclusions regarding efficacy and safety should be made.

*WI-NRS Success was assessed by caregivers using a WI-NRS validated in patients age 12+.

Not an actual patient.
Symptoms illustrated.

ZORYVE CREAM.
ONCE A DAY.
ANYWHERE.

Reliable results anywhere on the body with a once-daily topical1

See before & after photos

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.1

AGE 11 - ZORYVE 0.15%

Hand with atopic dermatitis before treatment - Baseline vIGA-AD = 3Hand with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

BASELINE

vIGA-AD = 3

WEEK 4

vIGA-AD = 1

AGE 2 – ZORYVE 0.05%

Gluteal region with atopic dermatitis before treatment - Baseline vIGA-AD = 2Gluteal region with atopic dermatitis on Week 4 of treatment - vIGA-AD = 0

BASELINE

vIGA-AD = 2

WEEK 4

vIGA-AD = 0

AGE 9 – ZORYVE 0.15%

Mouth with atopic dermatitis before treatment - Baseline vIGA-AD = 3Mouth with atopic dermatitis on Week 4 of treatment - vIGA-AD = 0

BASELINE

vIGA-AD = 3

WEEK 4

vIGA-AD = 0

Actual clinical trial patient.6 Individual results may vary.
vIGA-AD Scale: 4 = Severe, 3 = Moderate, 2 = Mild, 1 = Almost Clear, 0 = Clear.

ZORYVE Direct, Patient Access Support Made Easy

Committed to affordable patient access
across all indications

The ZORYVE Direct Savings Card Program helps eligible, commercially insured patients get access and start ZORYVE treatment quickly and easily†‡

Patient Access Support

Savings Program

Adherence Support

Learn about patient
access support

†Prescriptions will be delivered to the patient 1–2 days after processing.

‡Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.

Connect With Us

Request a
Representative